000			01615nam a22003497a 4500
008			210310s20212021 xxu||||| |||| 00| 0 eng d
022			_a0022-4790
024			_a10.1002/jso.26347 [doi]
040			_aOvid MEDLINE(R)
099			_a33595888
245			_aImmunotherapy in lung cancer. [Review]
251			_aJournal of Surgical Oncology. 123(3):718-729, 2021 Mar.
252			_aJ Surg Oncol. 123(3):718-729, 2021 Mar.
253			_aJournal of surgical oncology
260			_c2021
260			_fFY2021
265			_sppublish
266			_d2021-03-10
520			_aImmunotherapy has emerged as an important treatment modality throughout oncology with a particularly important role in the treatment of lung cancer. Early signals showed responses could be achieved in nonsmall cell lung cancer and small cell lung cancer and these monoclonal antibodies have become standards of care for advanced stage disease. They have also shown promise in earlier-stage disease as complements to radiation or surgery, offering the potential for durable, meaningful survival gains. Copyright (c) 2020 Wiley Periodicals LLC.
546			_aEnglish
650			_aIN PROCESS -- NOT YET INDEXED
651			_aMedStar Washington Hospital Center
656			_aHematology/Oncology
656			_aMedicine/General Internal Medicine
657			_aJournal Article
657			_aReview
700			_aFarid, Saira
700			_aMontenegro, Gabriela Bravo
790			_aFarid S, Liu SV, Montenegro GB
856			_uhttps://dx.doi.org/10.1002/jso.26347 _zhttps://dx.doi.org/10.1002/jso.26347
942			_cART _dArticle
999			_c6241 _d6241